Revolutionizing Respiratory Medicine: Diag-Nose.io Secures $2M Seed Funding to Advance AI-Driven Diagnostics

Key Highlights

• Diag-Nose.io raises $2M in an oversubscribed seed round to revolutionize respiratory disease management.
• Funding will advance AI-powered RhinoMAP™ and the ABEL Microsampler™ for personalized treatment.
• Backed by global investors, the company aims to transform chronic respiratory care worldwide.

Biotechnology innovator Diag-Nose.io has raised $2 million in an oversubscribed seed funding round, signaling a transformative step in the fight against chronic respiratory diseases. Emerging from Stanford University’s 2019 EENT Innovation Biodesign program, the company is poised to redefine global respiratory care through its cutting-edge AI-powered diagnostic platform, RhinoMAP™.

This funding will accelerate the development and implementation of RhinoMAP™, a groundbreaking system that combines artificial intelligence with proteomics to create precision treatments tailored to each patient's unique biological profile. This marks a significant shift from traditional diagnostic tools, which often lack the nuance needed for effective treatment of conditions like asthma, COPD, and chronic sinusitis.

Breaking Down the Innovation

At the core of Diag-Nose.io’s innovation is the ABEL Microsampler™, a patented nasal liquid biopsy device that enables the collection of nasal samples for analysis. By using this device in tandem with the AI-driven RhinoMAP™ platform, healthcare providers gain access to detailed insights into disease progression and treatment efficacy. This approach capitalizes on the "unified airway" concept, which emphasizes the interconnected biology of the lungs and nasal passages.

CEO and Co-Founder Eldin Rostom emphasized the urgency of this breakthrough:

"With over 40 million Americans and 450 million individuals globally suffering from chronic respiratory conditions, there is a critical need for innovation. Our RhinoMAP™ system, combined with emerging biologic therapies, brings us closer to helping patients achieve complete symptom relief."

Backing the Vision

Diag-Nose.io’s funding round attracted a diverse pool of international investors, including Breakthrough Victoria, Radar Ventures, and Specialty Physician Associates, alongside prominent biotech angel investors. Carl Stubbings, a key investor, has joined the company’s board as chairperson.

Stubbings praised the company’s vision, stating, "This is a revolutionary step in respiratory medicine. Personalizing treatments through AI-driven biomarker analysis could change millions of lives. I’m proud to support Diag-Nose.io as it takes RhinoMAP™ to the global stage."

A Global Push for Clinical Validation

The seed funding will support the launch of extensive clinical trials in the United States in 2025, aimed at refining and validating the RhinoMAP™ technology for global application. These trials will also position Diag-Nose.io as a leader in precision respiratory care, aligning it with academic and industry partners to expand the impact of its innovative solutions.

Why It Matters

Respiratory diseases remain a significant burden on global healthcare systems, accounting for approximately 4 million deaths annually as of 2019. Current diagnostic methods often lack precision, leading to delayed or ineffective treatments.

Diag-Nose.io’s AI-powered approach not only promises to improve diagnostic accuracy but also aims to optimize patient outcomes while reducing the systemic strain on healthcare infrastructure.

The Road Ahead

With its pioneering approach, strategic partnerships, and the trust of investors, Diag-Nose.io is set to redefine the landscape of respiratory care. As the company gears up for clinical trials and wider adoption, its transformative potential is already sparking excitement among stakeholders.

By harnessing the power of AI and the interconnected biology of the airway, Diag-Nose.io is paving the way for a future where respiratory conditions are not just managed but potentially eradicated.